Skip to content

ICYMI: Shaheen Ramps Up Push for Bipartisan Bill Capping Insulin Costs in Lame Duck Session

(Washington, DC) – In case you missed it, Senator Jeanne Shaheen (D-NH), Co-Chair of the U.S. Senate Diabetes Caucus, is pushing for passage of her bipartisan INSULIN Act to cap the monthly out-of-pocket cost of insulin at $35 before year’s end. In a recent Punchbowl News piece, Shaheen notes that the legislation is a clear way for Congress to lower costs in the wake of an election where voters made it clear that the skyrocketing cost of living is their top concern. The Punchbowl News article can be read HERE.

Key Excerpts:

  • “A bipartisan group of departing lawmakers is pushing to pass a bill in the lame duck that would cap the price of insulin at $35 per month in commercial insurance. It’s the last chance for this group of lawmakers to pass the legislation before they leave Congress for varying reasons at the end of this session.”
  • “‘Voters sent a clear message this election that Congress needs to take urgent action to lower costs for American families,’ Shaheen said in a statement.”
  • “But many Americans still struggle to afford insulin, according to diabetes advocacy organizations. A handful of groups, including the American Diabetes Association and the National Kidney Foundation, sent letters to the White House and to congressional leadership on Friday urging passage of the bill.”

Shaheen’s bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act would cap monthly out-of-pocket insulin costs at $35 for Americans with insurance, expanding the effective price cap for Americans on Medicare. Shaheen has championed efforts to lower insulin costs throughout her time in office, and the bill is closer than ever before to passing out of the U.S. Senate. In July, the INSULIN Act advanced out of the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee, and in September companion legislation was introduced in the U.S. House of Representatives.

Senator Shaheen has worked tirelessly to lower health care costs for Granite Staters and Americans. As co-chair of the U.S. Senate Diabetes Caucus, Senator Shaheen has consistently pressed to hold insulin manufacturers, insurers and pharmacy benefit managers accountable for the skyrocketing cost of life-saving insulin and otherwise support patients and families facing diabetes. Polling released from the American Diabetes Association this summer found that 40% of respondents who rely on insulin report paying more than $150 per month for insulin, and 76% of respondents across political parties support a $35 limit on cost sharing for insulin.

###